The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 3, 2017, Pages 502-510

  Luzum, J A ^a,b   Pakyz, R E ^c   Elsey, A R ^d   Haidar, C E ^e   Peterson, J F ^f   Whirl Carrillo, M ^h   Handelman, S K ^b   Palmer, K ^c   Pulley, J M ^g   Beller, M ^f   Schildcrout, J S ^f   Field, J R ^g   Weitzel, K W ^d   Cooper DeHoff, R M ^d   Cavallari, L H ^d   O'Donnell, P H ⁱ   Altman, R B ^h   Pereira, N ^j   Ratain, M J ⁱ   Roden, D M ^f   Embi, P J ^k   Sadee, W ^b   Klein, T E ^h   Johnson, J A ^d   Relling, M V ^e   Wang, L ^l   Weinshilboum, R M ^l   Shuldiner, A R ^c   Freimuth, R R ^j   more..

^a UNIVERSITY OF MICHIGAN   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ University of Chicago   (United States)

^j MAYO CLINIC   (United States)

^k OHIO STATE UNIVERSITY   (United States)

^l MAYO GRADUATE SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; BUDESONIDE; CAPECITABINE; CARBAMAZEPINE; CLOPIDOGREL; CODEINE; COTRIMOXAZOLE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; FOSPHENYTOIN SODIUM; GLUCURONOSYLTRANSFERASE 1A1; HLA B ANTIGEN; INTERLEUKIN 28; IRINOTECAN; IVACAFTOR; MEVINOLIN; RASBURICASE; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TACROLIMUS; TAMOXIFEN; TRIAMCINOLONE; WARFARIN;

ARTICLE; HAPLOTYPE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; NATIONAL HEALTH ORGANIZATION; PHARMACOGENETIC TESTING; PHARMACOGENETICS; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; ALLELE; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; PROCEDURES; TRANSLATIONAL RESEARCH; UNITED STATES;

ALLELES; DELIVERY OF HEALTH CARE; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 85020388874     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.630     Document Type: Article

References (44)

1. United States Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. .
2. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464–467 (2011).
3. Stanek, E.J. et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91, 450–458 (2012).
4. Shuldiner, A.R. et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin. Pharmacol. Ther. 94, 207–210 (2013).
5. Manolio, T.A. et al. Implementing genomic medicine in the clinic: the future is here. Genet. Med. 15, 258–267 (2013).
6. Hewett, M. et al. PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res. 30, 163–165 (2002).
7. Owusu-Obeng, A. et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy. 34, 1102–1112 (2014).
8. Hoffman, J.M. et al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am. J. Med. Genet. C Semin. Med. Genet. 166C, 45–55 (2014).
9. Khan, N.A. & Peterson, J.F. A surveillance tool to support quality assurance and research in personalized medicine. AMIA Annual Symposium proceedings AMIA Symposium. 2011, 701–708 (2011).
10. Sweet, K. et al. Design and implementation of a randomized controlled trial of genomic counseling for patients with chronic disease. J. Pers. Med. 4, 1–19 (2014).
11. Shuldiner, A.R. et al. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am. J. Med. Genet. C Semin. Med. Genet. 166C, 76–84 (2014).
12. Sturm, A.C., Sweet, K. & Manickam, K. Implementation of a clinical research pharmacogenomics program at an academic medical center: role of the genetics healthcare professional. Pharmacogenomics. 14, 703–706 (2013).
13. Peterson, J.F. et al. Physician response to implementation of genotype-tailored antiplatelet therapy. Clin. Pharmacol. Ther. 100, 67–74 (2016).
14. Weitzel, K.W. et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am. J. Med. Genet. C Semin. Med. Genet. 166C, 56–67 (2014).
15. O'Donnell, P.H. et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care—initial results of the University of Chicago “1,200 Patients Project.” Am. J. Med. Genet. C Semin. Med. Genet. 166C, 68–75 (2014).
16. Dolan, M.E. et al. Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. Pharmacogenomics. 14, 1383–1387 (2013).
17. Hussain, S. et al. Disease-drug database for pharmacogenomic-based prescribing. Clin. Pharmacol. Ther. 100, 179–190 (2016).
18. O'Donnell, P.H., Danahey, K. & Ratain, MJ. The outlier in all of us: why implementing pharmacogenomics could matter for everyone. Clin. Pharmacol. Ther. 99, 401–404 (2016).
19. Weitzel, K.W. et al. The IGNITE network: a model for genomic medicine implementation and research. BMC Med. Genomics. 9, 1 (2016).
20. Gottesman, O. et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet. Med. 15, 761–771 (2013).
21. Pereira, N.L., Sargent, D.J., Farkouh, M.E. & Rihal, C.S. Genotype-based clinical trials in cardiovascular disease. Nat. Rev. Cardiol. 12, 475–487 (2015).
22. Vanderbilt University. My Drug Genome. .
23. Mayo Clinic Center for Individualized Medicine. Pharmacogenomics Program. .
24. St. Jude Children's Research Hospital. PG4KDS: Clinical Implementation of Pharmacogenetics. .
25. Vanderbilt University. Vanderbilt Pharmacogenomics. .
26. University of Florida Health Personalized Medicine Program. .
27. University of Chicago Center for Personalized Therapeutics. .
28. EMERGE & IGNITE Networks. CDS_KB: Clinical Decision Support Knowledgebase. .
29. Vanderbilt University. Case Studies in Personalized Medicine. .
30. Ohio State University Center for Pharmacogenomics. How to Teach Pharmacogenomics. .
31. Kitzmiller, J.P., Phelps, M.A., Neidecker, M.V. & Apseloff, G. Establishing a clinical pharmacology fellowship program for physicians, pharmacists, and pharmacologists: a newly accredited interdisciplinary training program at the Ohio State University. Adv. Med. Educ. Pract. 5, 191–196 (2014).
32. Perry, C.G. et al. Educational innovations in clinical pharmacogenomics. Clin. Pharmacol. Ther. 99, 582–584 (2016).
33. Weitzel, K.W. et al. Effects of using personal genotype data on student learning and attitudes in a pharmacogenomics course. Am. J. Pharm. Educ. 80, 122 (2016).
34. Luzum, J.A. & Luzum, M.J. Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education. Pers. Med. 13, 119–127 (2016).
35. Reese, E.S., Daniel, Mullins C., Beitelshees, A.L. & Onukwugha, E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy. 32, 323–332 (2012).
36. Caudle, K.E. et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet. Med; e-pub ahead of print (2016).
37. Clinical Pharmacogenetics Implementation Consortium (CPIC). Implementation. .
38. Farrugia, G. & Weinshilboum, R.M. Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine. Clin. Pharmacol. Ther. 94, 204–206 (2013).
39. Bielinski, S.J. et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin. Proc. 89, 25–33 (2014).
40. Schildcrout, J.S. et al. A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program. J. Clin. Epidemiol. 72, 107–115 (2016).
41. Schildcrout, J.S. et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin. Pharmacol. Ther. 92, 235–242 (2012).
42. Peterson, J.F. et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet. Med. 15, 833–841 (2013).
43. Pulley, J.M. et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92, 87–95 (2012).
44. O'Donnell, P.H. et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin. Pharmacol. Ther. 92, 446–449 (2012).